Strategic Blueprint’s Haemonetics HAE Stock Holding History

Strategic Blueprint’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7	Closed	–	–	779
2021 Q2	$0	Buy	+7	New	+$495	﹤0.01%	1425

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Strategic Blueprint's HAE Position: Q3 2021 in Review

Strategic Blueprint sold out of Haemonetics (HAE) in Q3 2021, closing a stake of 7 shares.

Strategic Blueprint first reported a position in HAE in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

Strategic Blueprint reported no remaining Haemonetics position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 7 Haemonetics shares in Q3 2021.
Strategic Blueprint first reported a position in Haemonetics in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's Haemonetics position peaked at $0 in Q2 2021.
245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.